A pioneering blood test detected more than twice as many high-risk prostate cancer cases as current methods, paving the way for more effective screening.
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
Prostate cancer (PCa) is the second most common malignancy in men world-wide. Serum prostate-specific antigen (PSA) has been the common method of PCa diagnosis for decades 1. Recent randomised trials ...
Early findings show efficacy of water vapor therapy for treating intermediate-risk prostate cancer with minimal procedural ...
Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...
Prostate cancer remains a substantial health challenge, with >375,000 annual deaths amongst men worldwide. Most prostate cancer-related deaths are attributable to the development of resistance to ...
A multimodal AI model identified a subset of men with very high-risk localized prostate cancer who derived substantial ...
Millions of men face a decision about whether to be screened for prostate cancer. National guidelines say that decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results